Rare disease drug developer Egetis Q3 revenue rises on EMCITATE sales

Overview

• Sweden rare disease drug developer's Q3 net revenue rose 24% at CER, driven by EMCITATE sales

• Company posted a wider Q3 net loss

• FDA approved EMCITATE for MCT8 deficiency in the U.S. during the quarter

Outlook

• Company prioritizes successful U.S. launch of EMCITATE in 2026

• Company aims to optimize pricing and reimbursement and continue EMCITATE rollout in Europe

• Egetis plans to finalize tiratricol development plan for RTH-beta in 2026

Result Drivers

• FDA APPROVAL - EMCITATE received U.S. FDA approval for MCT8 deficiency, marking a key milestone for the company

• COMMERCIAL LAUNCH PREPARATIONS - Co said extensive preparations enabled rapid U.S. launch of EMCITATE and early physician uptake

• GERMANY SALES - Most Q3 EMCITATE sales came from Germany, where national reimbursement is in place

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Egetis Therapeutics AB (publ) is SEK18.00, about 80.2% above its November 4 closing price of SEK9.99

Reuters Recommended Reads

• Nov 4 - Sweden's Medicover Q3 profit rises 29% on price adjustments and wider network; to focus on Europe

• Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

• Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)